Treatment of unresectable pancreatic carcinoma with 5-fluorouracil, vincristine, and CCNU.
Forty-seven patients with unoperable pancreatic cancer were included in a controlled, prospective study of combination chemotherapy. Twenty-five of the patients were allocated to cyclic treatment with 5-fluorouracil, CCNU, and vincristine in accordance with a special schedule. The other 22 patients served as untreated controls. There were no differences between the two groups with regard to survival time or quality of life. Side effects of the drugs given were common in the treatment group.
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use*; D006801:Humans; D008130:Lomustine / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000401:mortality; D011379:Prognosis; D011446:Prospective Studies; D011897:Random Allocation; D014750:Vincristine / Q000627:therapeutic use*
D014750:Vincristine; D008130:Lomustine; D005472:Fluorouracil